Clinical

Articles

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.

Sunitinib Treatment Improved Survival for Malignant Pheochromocytoma and Paraganglioma

Patients with intermediate- and poor-risk metastatic renal cell carcinoma experienced promising responses after being treated with perioperative cabozantinib.

Perioperative Cabozantinib Demonstrates Promise in Metastatic Renal Cell Carcinoma

Those with advanced renal cell carcinoma whose disease was previously treated experienced long-lasting and robust overall survival following treatment with cabozantinib.

Cabozantinib Demonstrates Real-World Survival Benefit in Patients With Pre-Treated Advanced Renal Cell Carcinoma

Patients with VHL-mutant and wild type clear cell renal cell carcinoma may have comparable clinical characteristics, although other genetic alterations may be at play.

Similar Clinical Characteristics Could be Present in Both VHL-Mutant and Wild Type Clear Cell RCC

A lack of understanding, communication, and more was expressed among both patients and caregivers regarding a subtype of kidney cancer.

Communication Improvements Necessary for Understanding Aspects of Renal Cell Carcinoma

Videos

Around the Practice: High-Risk Renal Cell Carcinoma

High-Risk Renal Cell Carcinoma: 51-Year-Old Male

CancerNetwork spoke with Eric Jonasch, MD, about the NCCN’s recommendation and how thee multidisciplinary approach will play a role.

NCCN Recommends Frontline Lenvatinib/Pembrolizumab for Advanced RCC

Merck announced an interim analysis of pembrolizumab to treat RCC, finding a clinically significant improvement in disease-free survival when compared with placebo.

Pembrolizumab Monotherapy Improves DFS in Patients With Renal Cell Carcinoma

Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.

Ramaprasad Srinivasan, MD, PhD, on the Design of the Study of MK-6482 in VHL-Associated Disease

The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.

Kidney Cancer | Topics